1
Country: USA | Funding: $908.6M
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
2
Country: USA | Funding: $569.1M
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
3
Country: USA | Funding: $115.9M
Nurx is offering Truvada as "PrEP," or an HIV preexposure prophylaxis. People looking to get on PrEP can sign up via Nurx's website or smartphone app.
Nurx is offering Truvada as "PrEP," or an HIV preexposure prophylaxis. People looking to get on PrEP can sign up via Nurx's website or smartphone app.
4
Country: USA | Funding: $100M
Addition Therapeutics (University of California spinoff) develops RNA-only therapeutics using PRINT technology for genetic medicine. PRINT stands for Precise RNA-Mediated Insertion of Transgenes and involves the creation of all-RNA, non-viral lipid nanoparticles. In drugs created using PRINT technology, only the genetic sequence of the messenger RNA is altered, all other components remain unchanged. The company claims this enables the creation of safer, long-lasting, single-dose treatments that overcome the limitations of existing genetic medicine. One of the company's primary goals is the treatment of HIV. With a grant from the Gates Foundation, Addition is developing PRINT therapy to stimulate endogenous antibody production with a single dose for "lifelong protection against HIV."
Addition Therapeutics (University of California spinoff) develops RNA-only therapeutics using PRINT technology for genetic medicine. PRINT stands for Precise RNA-Mediated Insertion of Transgenes and involves the creation of all-RNA, non-viral lipid nanoparticles. In drugs created using PRINT technology, only the genetic sequence of the messenger RNA is altered, all other components remain unchanged. The company claims this enables the creation of safer, long-lasting, single-dose treatments that overcome the limitations of existing genetic medicine. One of the company's primary goals is the treatment of HIV. With a grant from the Gates Foundation, Addition is developing PRINT therapy to stimulate endogenous antibody production with a single dose for "lifelong protection against HIV."
5
Country: USA | Funding: $34.8M
Aethlon Medical creates immunotherapeutic devices to combat infectious disease and cancer.
Aethlon Medical creates immunotherapeutic devices to combat infectious disease and cancer.
6
Country: Germany | Funding: €301.4K
ImmunoLogik has identified an active agent that helps patients who have developed a resistance against standard HIV treatment therapies.
ImmunoLogik has identified an active agent that helps patients who have developed a resistance against standard HIV treatment therapies.
